ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 102 filers reported holding ESPERION THERAPEUTICS INC NE in Q3 2016. The put-call ratio across all filers is 0.55 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $1,503,000 | -73.2% | 900,000 | 0.0% | 0.16% | -71.8% |
| Q4 2022 | $5,607,000 | -23.4% | 900,000 | 0.0% | 0.58% | -23.6% |
| Q3 2022 | $7,317,000 | +27.8% | 900,000 | 0.0% | 0.77% | +17.8% |
| Q2 2022 | $5,724,000 | +25.7% | 900,000 | -8.3% | 0.65% | +44.8% |
| Q1 2022 | $4,555,000 | -8.2% | 981,582 | -1.8% | 0.45% | +36.1% |
| Q4 2021 | $4,960,000 | -33.8% | 1,000,000 | +60.7% | 0.33% | -37.3% |
| Q3 2021 | $7,498,000 | -38.0% | 622,267 | +8.7% | 0.53% | -36.0% |
| Q2 2021 | $12,103,000 | -27.1% | 572,267 | -3.4% | 0.82% | -29.0% |
| Q1 2021 | $16,612,000 | +7.9% | 592,225 | 0.0% | 1.16% | -7.8% |
| Q4 2020 | $15,398,000 | -9.0% | 592,225 | +30.2% | 1.26% | -16.5% |
| Q3 2020 | $16,912,000 | -22.4% | 455,000 | +7.1% | 1.50% | -36.2% |
| Q2 2020 | $21,807,000 | +16.7% | 425,000 | -28.3% | 2.36% | -10.0% |
| Q1 2020 | $18,691,000 | -52.5% | 592,798 | -10.2% | 2.62% | -39.3% |
| Q4 2019 | $39,356,000 | +63.7% | 660,000 | +0.6% | 4.31% | +43.1% |
| Q3 2019 | $24,044,000 | +25.4% | 655,854 | +59.2% | 3.01% | +42.7% |
| Q2 2019 | $19,171,000 | -0.5% | 412,093 | -14.1% | 2.11% | -6.3% |
| Q1 2019 | $19,263,000 | +18.3% | 479,767 | +35.5% | 2.25% | +21.1% |
| Q4 2018 | $16,282,000 | +3.7% | 353,961 | 0.0% | 1.86% | +18.2% |
| Q3 2018 | $15,705,000 | -1.4% | 353,961 | -12.9% | 1.57% | -3.4% |
| Q2 2018 | $15,925,000 | -10.0% | 406,361 | +66.2% | 1.63% | -25.2% |
| Q1 2018 | $17,688,000 | -30.5% | 244,540 | -36.8% | 2.18% | -36.6% |
| Q4 2017 | $25,455,000 | +62.9% | 386,626 | +24.0% | 3.44% | +72.4% |
| Q3 2017 | $15,628,000 | -7.1% | 311,803 | -14.2% | 2.00% | -17.4% |
| Q2 2017 | $16,816,000 | -12.4% | 363,347 | -33.1% | 2.41% | -20.5% |
| Q1 2017 | $19,186,000 | +457.2% | 543,347 | +97.6% | 3.04% | +360.3% |
| Q4 2016 | $3,443,000 | -99.8% | 275,000 | +111.5% | 0.66% | +130.8% |
| Q3 2016 | $1,800,500,000 | +130088.0% | 130,000 | -7.1% | 0.29% | +16.3% |
| Q2 2016 | $1,383,000 | -45.5% | 140,000 | -6.7% | 0.25% | -51.2% |
| Q1 2016 | $2,537,000 | +14.0% | 150,000 | +50.0% | 0.50% | +49.6% |
| Q4 2015 | $2,226,000 | -5.6% | 100,000 | 0.0% | 0.34% | -10.4% |
| Q3 2015 | $2,359,000 | -74.2% | 100,000 | -10.7% | 0.38% | -65.8% |
| Q2 2015 | $9,157,000 | -22.1% | 112,000 | -11.8% | 1.10% | -44.5% |
| Q1 2015 | $11,753,000 | +93.8% | 126,926 | -15.4% | 1.98% | +12.7% |
| Q4 2014 | $6,066,000 | +199.1% | 150,000 | +80.9% | 1.76% | +196.0% |
| Q3 2014 | $2,028,000 | – | 82,921 | – | 0.59% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 4,468,835 | $20,735,000 | 8.65% |
| Altium Capital Management LP | 2,496,524 | $11,584,000 | 3.88% |
| Deep Track Capital, LP | 6,000,000 | $27,840,000 | 1.78% |
| Paradigm Biocapital Advisors LP | 1,157,246 | $5,370,000 | 1.42% |
| Monaco Asset Management SAM | 419,262 | $1,945,000 | 0.77% |
| Rhenman & Partners Asset Management AB | 981,582 | $4,555,000 | 0.45% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,713,176 | $12,589,000 | 0.39% |
| Bellevue Group AG | 4,299,164 | $19,948,000 | 0.23% |
| WASATCH ADVISORS LP | 8,147,380 | $37,804,000 | 0.19% |
| Telemetry Investments, L.L.C. | 17,500 | $81,000 | 0.13% |